• Return to Headlines

Nektar Therapeutics Down 23.3% Since SmarTrend Downtrend Call (NKTR)

By Amy Schwartz

SmarTrend identified a Downtrend for Nektar Therapeutics (NASDAQ:NKTR) on September 27th, 2016 at $17.32. In approximately 3 weeks, Nektar Therapeutics has returned 23.30% as of today's recent price of $13.29.

Over the past year, Nektar Therapeutics has traded in a range of $9.16 to $19.98 and is now at $13.29, 45% above that low. Over the past week, the 200-day moving average (MA) has gone up 0.3% while the 50-day MA has advanced 2.1%.

Nektar Therapeutics (Nektar) is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.

SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any changes in momentum for shares of Nektar Therapeutics.

Log in and add Nektar Therapeutics (NKTR) to your watchlist today so you can receive a real-time alert when the shares are about to change trend.

Keywords: spotlights nektar therapeutics

Ticker(s): NKTR